[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CU24128B1 - Compuesto de benzoato conjugado a la hidrocodona (bz-hc) - Google Patents

Compuesto de benzoato conjugado a la hidrocodona (bz-hc)

Info

Publication number
CU24128B1
CU24128B1 CU2011000246A CU20110246A CU24128B1 CU 24128 B1 CU24128 B1 CU 24128B1 CU 2011000246 A CU2011000246 A CU 2011000246A CU 20110246 A CU20110246 A CU 20110246A CU 24128 B1 CU24128 B1 CU 24128B1
Authority
CU
Cuba
Prior art keywords
benzoate compound
hydrocodone
conjugated
hydrocodone conjugated
benzoate
Prior art date
Application number
CU2011000246A
Other languages
English (en)
Other versions
CU20110246A7 (es
Inventor
Travis Mickle
Sven Guenther
Christal Mickle
Gouchen Chi
Jaroslaw Kanski
Andrea K Martin
Bindu Bera
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43411452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24128(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of CU20110246A7 publication Critical patent/CU20110246A7/es
Publication of CU24128B1 publication Critical patent/CU24128B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de benzoato conjugado a la hidrocodona (BZ-HC) que tiene la estructura siguiente: Espacio para Fórmula.
CU2011000246A 2009-07-02 2010-07-01 Compuesto de benzoato conjugado a la hidrocodona (bz-hc) CU24128B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22271809P 2009-07-02 2009-07-02
PCT/US2010/040775 WO2011002991A1 (en) 2009-07-02 2010-07-01 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof

Publications (2)

Publication Number Publication Date
CU20110246A7 CU20110246A7 (es) 2012-04-15
CU24128B1 true CU24128B1 (es) 2015-09-29

Family

ID=43411452

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000246A CU24128B1 (es) 2009-07-02 2010-07-01 Compuesto de benzoato conjugado a la hidrocodona (bz-hc)

Country Status (21)

Country Link
US (14) US8759368B2 (es)
EP (2) EP3560336A1 (es)
JP (1) JP5442862B2 (es)
KR (5) KR102038260B1 (es)
CN (1) CN102480959B (es)
AU (1) AU2010266205B2 (es)
BR (1) BR112012000569B8 (es)
CA (1) CA2766388C (es)
CL (1) CL2011003347A1 (es)
CO (1) CO6480991A2 (es)
CR (1) CR20110688A (es)
CU (1) CU24128B1 (es)
IL (2) IL217096A (es)
MX (1) MX2012000128A (es)
MY (1) MY153046A (es)
NZ (1) NZ597235A (es)
RU (1) RU2505541C2 (es)
SG (1) SG177445A1 (es)
UA (1) UA102916C2 (es)
WO (1) WO2011002991A1 (es)
ZA (2) ZA201109438B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120142720A1 (en) * 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
WO2013063204A1 (en) * 2011-10-26 2013-05-02 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
KR101454515B1 (ko) * 2012-12-04 2014-10-23 바이오스펙트럼 주식회사 베라트릭 산 또는 이의 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 피부상태 개선용 조성물
US9815844B2 (en) 2013-03-08 2017-11-14 Kempharm, Inc. Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
EP3114601B1 (en) * 2014-03-07 2020-01-08 British Telecommunications public limited company Access control for a resource
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
SG11201704178UA (en) * 2014-11-25 2017-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
MX2017006935A (es) * 2014-12-02 2017-08-10 Kempharm Inc * Acido benzoico, derivados de acido benzoico y conjugados de acido heteroaril carboxilico de oximorfona, profarmacos, metodos de elaboracion y uso de los mismos.
KR20160097867A (ko) * 2015-02-10 2016-08-18 삼성전자주식회사 영상 표시 장치 및 영상 표시 방법
KR101669887B1 (ko) * 2015-03-05 2016-10-28 부산대학교 산학협력단 벤조인산을 유효성분으로 포함하는 임신 촉진용 조성물
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
US10449190B2 (en) * 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
KR101800834B1 (ko) 2016-07-20 2017-12-21 중앙대학교 산학협력단 아나카딕산을 유효성분으로 하는 배뇨 장애 예방 및 치료용 조성물
US10406153B2 (en) 2016-08-31 2019-09-10 Noramco, Inc. Process for the preparation of benzhydrocodone hydrochloride
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ
WO2018191474A1 (en) * 2017-04-14 2018-10-18 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
US11234975B2 (en) 2017-04-14 2022-02-01 Kempharm, Inc. Levorphanol prodrugs and processes for making and using them
US11214544B2 (en) 2017-04-14 2022-01-04 Kempharm, Inc. Dextrorphan prodrugs and processes for making and using them
JP7284764B2 (ja) * 2018-02-23 2023-05-31 ロデス テクノロジーズ 新規オピオイド化合物及びその使用
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (es)
US1731152A (en) * 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) * 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
GB2307833B (en) 1995-12-01 2000-06-07 Geco As A data compression method and apparatus for seismic data
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
TR200101932T2 (tr) * 1999-01-04 2001-11-21 Ml Laboratories Plc Gen terapisi-1
IL150929A0 (en) * 2000-01-28 2003-06-24 Rohm & Haas Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties
NZ529661A (en) 2001-06-05 2006-03-31 Control Delivery Systems Sustained-release analgesic compounds
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
ES2500117T3 (es) * 2002-02-22 2014-09-30 Shire Llc Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas
US20040058946A1 (en) 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
EP1782834A3 (en) 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
ATE454169T1 (de) 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
CA2540678C (en) 2003-09-30 2011-02-22 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
CA2541371C (en) 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
US20050203115A1 (en) 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
BRPI0510776A (pt) 2004-06-04 2007-11-20 Xenoport Inc pró-fármacos de levodopa, e suas composições e usos
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
CA2649360A1 (en) 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
RU2469038C2 (ru) 2006-05-26 2012-12-10 Фармакофор, Инк. Контролируемое высвобождение фенольных опиатов
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
EP3292866B1 (en) * 2006-10-20 2023-07-26 Johnson & Johnson Consumer Inc. Acetaminophen / ibuprofen combinations
US8067596B2 (en) * 2007-12-17 2011-11-29 Mallinckrodt Llc Processes for the production of (+)- “Nal” morphinan compounds
US20120142720A1 (en) 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
WO2011008636A1 (en) * 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives
DK2663187T3 (en) 2011-01-11 2016-08-29 Signature Therapeutics Inc Compositions comprising enzyme-cleavable oxycodone prodrug
WO2013063204A1 (en) 2011-10-26 2013-05-02 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
SG11201704178UA (en) 2014-11-25 2017-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Also Published As

Publication number Publication date
US8748413B2 (en) 2014-06-10
KR20170124638A (ko) 2017-11-10
SG177445A1 (en) 2012-02-28
US20160193204A1 (en) 2016-07-07
US20180177883A1 (en) 2018-06-28
KR101655972B1 (ko) 2016-09-08
JP5442862B2 (ja) 2014-03-12
US20120142719A1 (en) 2012-06-07
EP2448407A1 (en) 2012-05-09
US10577376B2 (en) 2020-03-03
CN102480959A (zh) 2012-05-30
IL217096A0 (en) 2012-02-29
US20150335759A1 (en) 2015-11-26
CL2011003347A1 (es) 2012-07-13
US20180104352A1 (en) 2018-04-19
ZA201109438B (en) 2013-05-29
US20130252994A1 (en) 2013-09-26
US8927716B2 (en) 2015-01-06
US9132125B2 (en) 2015-09-15
AU2010266205B2 (en) 2013-08-15
CN102480959B (zh) 2014-05-21
RU2012103476A (ru) 2013-08-10
AU2010266205A1 (en) 2012-02-02
US20150087667A1 (en) 2015-03-26
MY153046A (en) 2014-12-31
US8759368B2 (en) 2014-06-24
US20110002990A1 (en) 2011-01-06
US8461137B2 (en) 2013-06-11
KR101971223B1 (ko) 2019-04-23
US10654863B2 (en) 2020-05-19
JP2012532142A (ja) 2012-12-13
KR101795330B1 (ko) 2017-11-07
US10358452B2 (en) 2019-07-23
KR20180081176A (ko) 2018-07-13
US8828978B2 (en) 2014-09-09
US10351573B2 (en) 2019-07-16
KR102038260B1 (ko) 2019-10-29
US9872915B2 (en) 2018-01-23
EP3560336A1 (en) 2019-10-30
IL259889A (en) 2018-07-31
KR20190042115A (ko) 2019-04-23
US9549923B2 (en) 2017-01-24
US20130245265A1 (en) 2013-09-19
CA2766388A1 (en) 2011-01-06
CU20110246A7 (es) 2012-04-15
UA102916C2 (uk) 2013-08-27
IL217096A (en) 2015-06-30
CR20110688A (es) 2012-03-22
MX2012000128A (es) 2012-04-30
US20170226118A1 (en) 2017-08-10
EP2448407B1 (en) 2019-09-25
KR101877467B1 (ko) 2018-07-11
BR112012000569B8 (pt) 2021-05-25
ZA201300747B (en) 2014-09-25
US9650387B2 (en) 2017-05-16
US20130259909A1 (en) 2013-10-03
US20150065536A1 (en) 2015-03-05
CO6480991A2 (es) 2012-07-16
KR20160106781A (ko) 2016-09-12
US20160200731A1 (en) 2016-07-14
KR20120048589A (ko) 2012-05-15
BR112012000569A2 (pt) 2015-09-15
WO2011002991A1 (en) 2011-01-06
CA2766388C (en) 2014-05-27
US20170143696A1 (en) 2017-05-25
RU2505541C2 (ru) 2014-01-27
BR112012000569B1 (pt) 2021-02-02
NZ597235A (en) 2013-08-30
EP2448407A4 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
CU24128B1 (es) Compuesto de benzoato conjugado a la hidrocodona (bz-hc)
CL2016001732A1 (es) Métodos sintéticos para compuestos espiro-oxoindol (div. sol. 3633-13).
BR112013004494A2 (pt) suporte de montagem para parede para um conjunto de pista, e conjunto de pista.
UA107791C2 (en) Pesticidal compositions
CL2012002252A1 (es) Conjunto antidesgaste que incluye un elemento antidesgaste que va a montarse en un implemento o aparato que va a protegerse, un elemento de base que va a acoplarse al implemento o aparato, un elemento de bloqueo para bloquear dicho elemento antidesgaste con respecto a dicho elemento de base; base para un conjunto antidesgaste; bloqueo ; elemento de bloqueo; conjunto antidesgaste.
BRPI0912142A2 (pt) montagem de blindagem para sistemas de infusão
IN2012DN06714A (es)
UY31688A1 (es) Plaguicidas
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
BRPI1008949A2 (pt) Cetoenóis haloalquilmetilenóxi-fenil-substituídos.
UY32481A (es) Derivados de benzofurano
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
CR20130539A (es) Triazolopiridinas
WO2013055132A3 (ko) 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
UY34442A (es) 2-tiopirimidinonas.
BRPI1008946A2 (pt) um processo para a síntese de metanol.
CR20110581A (es) Preparación de solido
IN2014CN04960A (es)
BRPI1015022A2 (pt) mineração subterrânea.
BRPI0912716A2 (pt) composto.
EA201390951A1 (ru) Звукоизолирующий конструктивный элемент
IT1394901B1 (it) Struttura di lampada.
IT1403445B1 (it) Struttura della porzione posteriore di un veicolo.
IT1404114B1 (it) Procedimento per la curvatura di un pannello di resina.
UA70144U (ru) Устройство защиты воздушной линии электропередачи от повреждений птицами

Legal Events

Date Code Title Description
FG Grant of patent